Skip to main content

All Access Subscription

Get unlimited access to our full publication and article library.

Get Access Now

Interested in Group Sales? Learn more

After more than two years of questions raised by clinical data concerning the safety and efficacy of drug-eluting stents (DES), declines in the sales of DES devices because of these questions, and DES developers looking for R&D and regulatory guidance, FDA last month issued a new set of guidelines, in draft form, concerning the development, testing and manufacture of DES devices.

FDA draft guidance poised to raise bar higher for DES